The end of 23andMe's drug discovery dream

Plus: OpenAI tech in cancer care

November 12, 2024 Check out STAT+

Sponsored By

Health care and biotech may be facing unprecedented change under Trump's leadership. Join STAT reporters LIVE on LinkedIn today at 1 p.m. ET for insights from STAT's top DC and biotech journalists on what's at stake.

Emma McIntyre/Getty Images for MAKERS STAT+ | The end of 23andMe's drug discovery dream The genetics startup announced it would lay off 40% of its workforce and halt its efforts to develop new medicines, once a cornerstone of its strategy. By Matthew Herper STAT+ | OpenAI isn't built for health care. So why is its tech already in hospitals, pharma, and cancer care? Health care users are applying OpenAi and ChatGpt to speed up workflow, from summarizing medical records to offering treatment plans. By Mohana Ravindranath STAT+ | How Pfizer used wearables to tap into the promise of an experimental drug Pfizer's latest results on ponsegromab included endpoints data from advanced digital tech, top exec calls it 'a revolution' in how clinical trials are run. By Mario Aguilar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser